Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer.

Yesterday, July 16, 2015, 40 U.S. common stocks issued filings of shares being bought or sold by insiders. The transactions ranged in value from $173.13 to $2,117,222.29.

Highlighted Stocks Traded by Insiders:

LKQ (LKQ) - FREE Research Report

Holsten Joseph M, who is Director at LKQ, sold 9,391 shares at $30.79 on July 16, 2015. Following this transaction, the Director owned 272,729 shares meaning that the stake was reduced by 3.33% with the 9,391-share transaction.

Alberico Robert A, who is Senior VP of Human Resources at LKQ, sold 464 shares at $30.79 on July 16, 2015. Following this transaction, the Senior VP of Human Resources owned 14,942 shares meaning that the stake was reduced by 3.01% with the 464-share transaction.

The shares most recently traded at $31.09, up $0.30, or 0.95% since the insider transaction. Historical insider transactions for LKQ go as follows:

  • 4-Week # shares bought: 10,000
  • 4-Week # shares sold: 6,425
  • 12-Week # shares bought: 10,000
  • 12-Week # shares sold: 6,425
  • 24-Week # shares bought: 10,000
  • 24-Week # shares sold: 6,425

The average volume for LKQ has been 1.6 million shares per day over the past 30 days. LKQ has a market cap of $9.4 billion and is part of the consumer goods sector and automotive industry. Shares are up 10.85% year-to-date as of the close of trading on Thursday.

LKQ Corporation, together with its subsidiaries, distributes replacement parts, components, and systems used in the repair and maintenance of vehicles in the United States, the United Kingdom, the Netherlands, Belgium, Northern France, Canada, Mexico, and Central America. The company has a P/E ratio of 24.6. Currently, there are 8 analysts who rate LKQ a buy, no analysts rate it a sell, and none rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on LKQ - FREE

TheStreet Quant Ratings rates LKQ as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, solid stock price performance, increase in net income, growth in earnings per share and good cash flow from operations. Although the company may harbor some minor weaknesses, we feel they are unlikely to have a significant impact on results. Get the full LKQ Ratings Report from TheStreet Quant Ratings now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

Thermo Fisher Scientific (TMO) - FREE Research Report

Thomson Andrew J, who is Senior Vice President at Thermo Fisher Scientific, sold 5,000 shares at $135.23 on July 16, 2015. Following this transaction, the Senior Vice President owned 55,614 shares meaning that the stake was reduced by 8.25% with the 5,000-share transaction.

The shares most recently traded at $135.32, up $0.09, or 0.07% since the insider transaction. Historical insider transactions for Thermo Fisher Scientific go as follows:

  • 4-Week # shares sold: 10,000
  • 12-Week # shares sold: 10,000
  • 24-Week # shares sold: 100,696

The average volume for Thermo Fisher Scientific has been 1.7 million shares per day over the past 30 days. Thermo Fisher Scientific has a market cap of $53.8 billion and is part of the health care sector and health services industry. Shares are up 9.07% year-to-date as of the close of trading on Thursday.

Thermo Fisher Scientific Inc. provides analytical instruments, equipment, reagents and consumables, software, and services for research, manufacturing, analysis, discovery, and diagnostics worldwide. The stock currently has a dividend yield of 0.44%. The company has a P/E ratio of 31.4. Currently, there are 13 analysts who rate Thermo Fisher Scientific a buy, no analysts rate it a sell, and none rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on TMO - FREE

TheStreet Quant Ratings rates Thermo Fisher Scientific as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, reasonable valuation levels, expanding profit margins, largely solid financial position with reasonable debt levels by most measures and solid stock price performance. We feel its strengths outweigh the fact that the company has had sub par growth in net income. Get the full Thermo Fisher Scientific Ratings Report from TheStreet Quant Ratings now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

Culp (CFI) - FREE Research Report

Mcallister Kenneth W, who is Director at Culp, sold 5,000 shares at $32.74 on July 16, 2015. Following this transaction, the Director owned 19,917 shares meaning that the stake was reduced by 20.07% with the 5,000-share transaction.

The shares most recently traded at $32.75, up $0.01, or 0.03% since the insider transaction. Historical insider transactions for Culp go as follows:

  • 4-Week # shares sold: 15,000
  • 12-Week # shares sold: 15,000
  • 24-Week # shares sold: 40,000

The average volume for Culp has been 86,800 shares per day over the past 30 days. Culp has a market cap of $393.8 million and is part of the industrial goods sector and industrial industry. Shares are up 50.55% year-to-date as of the close of trading on Thursday.

Culp, Inc. manufactures, sources, markets, and sells mattress fabrics and upholstery fabrics to the furniture and bedding industries in North America and internationally. The company operates through two segments, Mattress Fabrics and Upholstery Fabrics. The stock currently has a dividend yield of 0.74%. The company has a P/E ratio of 31.0. Currently, there is 1 analyst who rates Culp a buy, no analysts rate it a sell, and 1 rates it a hold.

Exclusive Offer: Get the latest Stock Analysis on CFI - FREE

TheStreet Quant Ratings rates Culp as a buy. The company's strengths can be seen in multiple areas, such as its increase in net income, revenue growth, largely solid financial position with reasonable debt levels by most measures, reasonable valuation levels and solid stock price performance. We feel its strengths outweigh the fact that the company has had somewhat disappointing return on equity. Get the full Culp Ratings Report from TheStreet Quant Ratings now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.